Glutamate and post-traumatic stress disorder

toward a psychobiology of dissociation.

R. Chambers, J. D. Bremner, B. Moghaddam, S. M. Southwick, D. S. Charney, J. H. Krystal

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Dissociative cognitive and perceptual alterations commonly occur at the time of traumatization and as an enduring feature of post-traumatic stress disorder (PTSD). After stress exposure, dissociative symptoms are a predictor of the development of PTSD. Recent preclinical data suggest that stress stimulates the cortico-limbic release of glutamate. The glutamate that is released during stress in animal models influences behavior, induces a variety of changes in neural plasticity that may have long-lasting effects on brain function and behavior, and contributes to neural toxicity. Antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor also stimulates transient cortico-limbic glutamate release in animals. Further, some of the effects of NMDA antagonists in animals are blocked by drugs that attenuate glutamate release. Clinical studies suggest that NMDA antagonists may transiently stimulate glutamate release and produce symptoms resembling dissociative states in humans. A recent study suggests that a drug that reduces glutamate release also attenuates the perceptual effects of the NMDA antagonist, ketamine, in humans. Because of the possible contributions of hyperglutamatergic states to the acute and long-lasting consequences of traumatic stress exposure, the therapeutic and neuroprotective potential of drugs that attenuate glutamate release should be explored in traumatized individuals with dissociative symptoms.

Original languageEnglish (US)
Pages (from-to)274-281
Number of pages8
JournalSeminars in Clinical Neuropsychiatry
Volume4
Issue number4
StatePublished - Oct 1999
Externally publishedYes

Fingerprint

Dissociative Disorders
Post-Traumatic Stress Disorders
Glutamic Acid
N-Methylaspartate
Neuronal Plasticity
Glutamate Receptors
Ketamine
Neuroprotective Agents
Pharmaceutical Preparations
Animal Models
Brain

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)

Cite this

Chambers, R., Bremner, J. D., Moghaddam, B., Southwick, S. M., Charney, D. S., & Krystal, J. H. (1999). Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Seminars in Clinical Neuropsychiatry, 4(4), 274-281.

Glutamate and post-traumatic stress disorder : toward a psychobiology of dissociation. / Chambers, R.; Bremner, J. D.; Moghaddam, B.; Southwick, S. M.; Charney, D. S.; Krystal, J. H.

In: Seminars in Clinical Neuropsychiatry, Vol. 4, No. 4, 10.1999, p. 274-281.

Research output: Contribution to journalArticle

Chambers, R, Bremner, JD, Moghaddam, B, Southwick, SM, Charney, DS & Krystal, JH 1999, 'Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation.', Seminars in Clinical Neuropsychiatry, vol. 4, no. 4, pp. 274-281.
Chambers R, Bremner JD, Moghaddam B, Southwick SM, Charney DS, Krystal JH. Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Seminars in Clinical Neuropsychiatry. 1999 Oct;4(4):274-281.
Chambers, R. ; Bremner, J. D. ; Moghaddam, B. ; Southwick, S. M. ; Charney, D. S. ; Krystal, J. H. / Glutamate and post-traumatic stress disorder : toward a psychobiology of dissociation. In: Seminars in Clinical Neuropsychiatry. 1999 ; Vol. 4, No. 4. pp. 274-281.
@article{fdcf0901bf7a4aa2a6c9a9c8a1d4c0c1,
title = "Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation.",
abstract = "Dissociative cognitive and perceptual alterations commonly occur at the time of traumatization and as an enduring feature of post-traumatic stress disorder (PTSD). After stress exposure, dissociative symptoms are a predictor of the development of PTSD. Recent preclinical data suggest that stress stimulates the cortico-limbic release of glutamate. The glutamate that is released during stress in animal models influences behavior, induces a variety of changes in neural plasticity that may have long-lasting effects on brain function and behavior, and contributes to neural toxicity. Antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor also stimulates transient cortico-limbic glutamate release in animals. Further, some of the effects of NMDA antagonists in animals are blocked by drugs that attenuate glutamate release. Clinical studies suggest that NMDA antagonists may transiently stimulate glutamate release and produce symptoms resembling dissociative states in humans. A recent study suggests that a drug that reduces glutamate release also attenuates the perceptual effects of the NMDA antagonist, ketamine, in humans. Because of the possible contributions of hyperglutamatergic states to the acute and long-lasting consequences of traumatic stress exposure, the therapeutic and neuroprotective potential of drugs that attenuate glutamate release should be explored in traumatized individuals with dissociative symptoms.",
author = "R. Chambers and Bremner, {J. D.} and B. Moghaddam and Southwick, {S. M.} and Charney, {D. S.} and Krystal, {J. H.}",
year = "1999",
month = "10",
language = "English (US)",
volume = "4",
pages = "274--281",
journal = "Seminars in Clinical Neuropsychiatry",
issn = "1084-3612",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Glutamate and post-traumatic stress disorder

T2 - toward a psychobiology of dissociation.

AU - Chambers, R.

AU - Bremner, J. D.

AU - Moghaddam, B.

AU - Southwick, S. M.

AU - Charney, D. S.

AU - Krystal, J. H.

PY - 1999/10

Y1 - 1999/10

N2 - Dissociative cognitive and perceptual alterations commonly occur at the time of traumatization and as an enduring feature of post-traumatic stress disorder (PTSD). After stress exposure, dissociative symptoms are a predictor of the development of PTSD. Recent preclinical data suggest that stress stimulates the cortico-limbic release of glutamate. The glutamate that is released during stress in animal models influences behavior, induces a variety of changes in neural plasticity that may have long-lasting effects on brain function and behavior, and contributes to neural toxicity. Antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor also stimulates transient cortico-limbic glutamate release in animals. Further, some of the effects of NMDA antagonists in animals are blocked by drugs that attenuate glutamate release. Clinical studies suggest that NMDA antagonists may transiently stimulate glutamate release and produce symptoms resembling dissociative states in humans. A recent study suggests that a drug that reduces glutamate release also attenuates the perceptual effects of the NMDA antagonist, ketamine, in humans. Because of the possible contributions of hyperglutamatergic states to the acute and long-lasting consequences of traumatic stress exposure, the therapeutic and neuroprotective potential of drugs that attenuate glutamate release should be explored in traumatized individuals with dissociative symptoms.

AB - Dissociative cognitive and perceptual alterations commonly occur at the time of traumatization and as an enduring feature of post-traumatic stress disorder (PTSD). After stress exposure, dissociative symptoms are a predictor of the development of PTSD. Recent preclinical data suggest that stress stimulates the cortico-limbic release of glutamate. The glutamate that is released during stress in animal models influences behavior, induces a variety of changes in neural plasticity that may have long-lasting effects on brain function and behavior, and contributes to neural toxicity. Antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor also stimulates transient cortico-limbic glutamate release in animals. Further, some of the effects of NMDA antagonists in animals are blocked by drugs that attenuate glutamate release. Clinical studies suggest that NMDA antagonists may transiently stimulate glutamate release and produce symptoms resembling dissociative states in humans. A recent study suggests that a drug that reduces glutamate release also attenuates the perceptual effects of the NMDA antagonist, ketamine, in humans. Because of the possible contributions of hyperglutamatergic states to the acute and long-lasting consequences of traumatic stress exposure, the therapeutic and neuroprotective potential of drugs that attenuate glutamate release should be explored in traumatized individuals with dissociative symptoms.

UR - http://www.scopus.com/inward/record.url?scp=0033210095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033210095&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 274

EP - 281

JO - Seminars in Clinical Neuropsychiatry

JF - Seminars in Clinical Neuropsychiatry

SN - 1084-3612

IS - 4

ER -